“…Peptidomimetics guarantee enhanced protection against peptidases, improved systemic delivery and cell penetration, high target specificity and poor immune response and they are already in use against different pathologies, such as cancer and diabetes (Vagner et al, 2008;Zhang et al, 2018). In this context, computational approaches such as MetaD (Figure 2A) and classical MD simulations ( Figure 2B) demonstrated to be valid tools to drive the conversion of peptides in more active peptoids/peptidomimetics, targeting αvβ6 RGD-integrin in one case (Di Leva et al, 2018) and the eukaryotic translation initiation factor 4E (eIF4E) in the other (Lama et al, 2013(Lama et al, , 2019.…”